New hope for Parkinson's drooling: drug trial shows promise

NCT ID NCT06319118

Completed Symptom relief Sponsor: Second Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether dihydroergotine mesylate extended-release tablets can reduce drooling in people with Parkinson's disease. 120 patients took either the drug or a placebo for 12 weeks. Researchers measured changes in saliva weight and also looked at effects on thinking skills.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dihydroergotine mesylate extended-release tablets
What this could lead to: If it works, this could provide a new option to reduce drooling and possibly improve cognitive function in people with Parkinson's disease.
What could go wrong: This is a small, completed phase 4 trial with only 120 participants. The results may not apply to all Parkinson's patients, and the drug may cause side effects or fail to show a meaningful benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SALIVATION IN PARKINSON'S DISEASE

Contacts and locations

Locations

The Second Arilliated Hospital of Soochow University

Suzhou, Jiangsu, 215004, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.